Cannabidiol for craving and relapse in cocaine use disorder: RCT

Introduction and clinical context

The study Cannabidiol for craving and relapse in cocaine use disorder: RCT (PubMed · 2021) is part of the scientific research on the use of cannabinoids in cocaine and stimulants.

In cocaine and crack use disorder, cannabidiol (CBD) is investigated as a possible aid in reducing craving and preventing relapse. Randomized trials and exploratory studies evaluated CBD doses with results that are still mixed. The content is scientific and aimed at treatment and harm reduction; managing the dependence is multidisciplinary and led by healthcare professionals.

Understanding what science shows about the use of cannabinoids in cocaine and stimulants helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. RCT (78 adults): CBD 800 mg/day vs placebo for craving and relapse prevention in cocaine use. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In cocaine use disorder, CBD is investigated for modulating reward circuits and the stress response, with the hypothesis of reducing craving and relapse vulnerability, without the abuse potential of stimulants. It is generally well tolerated, but can cause drowsiness and appetite changes, with attention to drug interactions; the results are still mixed. The content is aimed at treatment and harm reduction, and managing the dependence is multidisciplinary, led by healthcare professionals.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2021). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD treat cocaine dependence?

It is investigated for craving and relapse, with results still mixed; management is multidisciplinary.

Is this content informative?

Yes, with a scientific and harm-reduction focus; it does not replace specialized treatment.